GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Ending Cash Position

TNF Pharmaceuticals (LTS:0A8D) Ending Cash Position : $1.19 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Ending Cash Position?

TNF Pharmaceuticals's Ending Cash Position for the quarter that ended in Sep. 2024 was $1.19 Mil.

TNF Pharmaceuticals's quarterly Ending Cash Position increased from Mar. 2024 ($0.23 Mil) to Jun. 2024 ($0.54 Mil) and increased from Jun. 2024 ($0.54 Mil) to Sep. 2024 ($1.19 Mil).

TNF Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 ($0.56 Mil) to Dec. 2022 ($0.75 Mil) and increased from Dec. 2022 ($0.75 Mil) to Dec. 2023 ($2.68 Mil).


TNF Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for TNF Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Ending Cash Position Chart

TNF Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Ending Cash Position
0.15 0.56 0.75 2.68

TNF Pharmaceuticals Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 2.68 0.23 0.54 1.19

TNF Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TNF Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.749+1.932
=2.68

TNF Pharmaceuticals's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.536+0.656
=1.19


TNF Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


TNF Pharmaceuticals Business Description

Traded in Other Exchanges
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Headlines

No Headlines